市场调查报告书
商品编码
1543631
生物技术领域的商业合作交易(2019-2024)Collaboration Deals in Biotechnology 2019-2024 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
本报告深入了解并分析公司如何以及为何进行业务合作交易。
本报告提供了2019年至2024年商业伙伴关係交易的详细资讯。
本报告提供了双方宣布的业务合作案件的付款条件。这些资料提供了有关支付条款和其他交易条款的宝贵见解。
了解潜在合作伙伴谈判条款的弹性,并深入了解谈判过程,以了解条款谈判期间的预期结果。许多小型企业会要求提供付款条件的详细信息,但在包括付款方式和权利如何转让时,细节是关键。
本报告提供了自2019年以来宣布的业务合作案件,全面列出目前协议案件/合作伙伴资料库中记录的内容,并包括可用的财务条款,以及公司及其合作伙伴向证券交易委员会提交的实际许可协议文件的线上副本的连结。
本报告为读者提供了以下主要好处:
此报告包含以下资讯:
此报告列出了可获得资讯的交易:
合约分析允许实质审查:
Collaboration Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter collaboration deals.
Fully revised and updated, the report provides details of collaboration deals from 2019 to 2024.
The report provides access to collaboration deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaboration contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of collaboration dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in collaboration as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of collaboration deals.
Chapter 4 provides a review of the leading collaboration deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active collaboration dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of collaboration deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the collaboration deal.
The deal directory includes a comprehensive listing of all collaboration deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in collaboration dealmaking since 2019.
In conclusion, this report provides everything a prospective dealmaker needs to know about collaboration alliances.
Collaboration Deals in Biotechnology provides the reader with the following key benefits:
Collaboration Deals in Biotechnology includes:
In Collaboration Deals in Biotechnology, the available deals are listed by:
Analyzing contract agreements allows due diligence of: